Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

2.0K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.0K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.9K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.9K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

3.0K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.0K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

1.1K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

5.7K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same author

TQC3721: Expanding the Role of Dual Phosphodiesterase 3/4 Inhibition in COPD Management.

Chest·2026
Same author

Mucus plugs in COPD and cardiovascular mortality: An emerging risk pathway and the therapeutic potential of mucolytic strategies.

Respiratory medicine·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.

Expert review of respiratory medicine·2026
Same author

Redox signaling in chronic airway diseases: pathogenic mechanisms and therapeutic implications.

Frontiers in physiology·2026

Related Experiment Video

Updated: Mar 13, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

14.1K

Muscarinic Receptor Antagonists.

Maria Gabriella Matera1, Mario Cazzola2

  • 1Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy.

Handbook of Experimental Pharmacology
|October 28, 2016
PubMed
Summary

Muscarinic receptor antagonists effectively treat airway obstruction in COPD and asthma by blocking parasympathetic activity. New long-acting muscarinic antagonists (LAMAs) offer improved safety and therapeutic benefits, with ongoing research for novel compounds.

Keywords:
Antimuscarinic agentsFixed-dose combinationsInhaled corticosteroidsβ2-agonists

More Related Videos

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

21.4K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.9K

Related Experiment Videos

Last Updated: Mar 13, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

14.1K
In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

21.4K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.9K

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Increased parasympathetic activity contributes significantly to reversible airway obstruction in COPD and asthma.
  • The cholinergic system influences airway smooth muscle, inflammatory cells, and epithelial cells, suggesting broader therapeutic roles for muscarinic antagonists.

Purpose of the Study:

  • To review the role of muscarinic receptor antagonists in managing COPD and asthma.
  • To discuss current and emerging muscarinic receptor antagonists, including short-acting (SAMAs) and long-acting (LAMAs) agents.
  • To explore potential additional clinical benefits and safety profiles of these agents.

Main Methods:

  • Literature review of studies on muscarinic receptor antagonists in COPD and asthma.
  • Analysis of current therapeutic options, including SAMAs (ipratropium, oxitropium) and LAMAs (aclidinium, tiotropium, glycopyrronium, umeclidinium).
  • Examination of safety data, particularly cardiovascular concerns, and potential synergistic effects with other respiratory medications.

Main Results:

  • Muscarinic receptor antagonists are effective bronchodilators for COPD and asthma.
  • Several LAMAs are approved for COPD treatment, with tiotropium bromide being significant for maintenance therapy.
  • Emerging LAMAs show promise, and advanced compounds appear to have improved cardiovascular safety profiles.
  • Combination therapy with SAMAs/LAMAs and other treatments (LABAs, ICS, PDE4 inhibitors) provides additional benefits.

Conclusions:

  • Muscarinic receptor antagonists are crucial in managing COPD and asthma, offering bronchodilation and potentially other beneficial effects.
  • Long-acting muscarinic antagonists (LAMAs) are key in maintenance therapy, and research is ongoing to develop new agents with enhanced safety and efficacy.
  • While cardiovascular safety concerns exist, newer agents demonstrate improved profiles, supporting their role in comprehensive respiratory care.